---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-025377"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2022-02-22T23:59:59+00:00"
generated_at: "2026-06-27T06:13:20.371702+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kiniksa and Huadong Medicine $22M upfront Asia Pacific deal; ARCALYST FY2022 rev guidance $115-130M

## Summary
- Upfront $22M from Huadong; up to $640M milestones + low-teens to low-twenties royalties on net sales for ARCALYST and mavrilimumab in Asia Pacific (ex-Japan).
- ARCALYST net revenue $18.7M Q4 2021, $38.5M FY2021; collaboration achieved profitability in Q4.
- FY2022 ARCALYST net revenue guidance $115-130M; cash $182.2M, no debt, funded into 2024.
- No Phase 3 for mavrilimumab in giant cell arteritis; vixarelimab Phase 2b data in prurigo nodularis expected H2 2022.
- Net loss $36.3M Q4 2021 vs $53.7M Q4 2020; full-year net loss $157.9M vs $161.4M in 2020.

## SEC filing metadata
- accession: 0001104659-22-025377
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2022-02-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465922025377/0001104659-22-025377-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465922025377/tm227059d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-025377
- JSON: https://secwatch.observer/filing/0001104659-22-025377.json
- Plain text: https://secwatch.observer/filing/0001104659-22-025377.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.